Masahiro Inoue, Jeffrey H. Hager, Napoleone Ferrara, Hans-Peter Gerber, Douglas Hanahan: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. In: Cancer Cell. Band 1, Nr. 2, März 2002, S. 193–202, doi:10.1016/S1535-6108(02)00031-4. PMID 12086877.
Peter Baluk, Hiroya Hashizume, Donald M. McDonald: Cellular abnormalities of blood vessels as targets in cancer. In: Current opinion in genetics & development. Band 15, Nr. 1, Februar 2005, S. 102–111, doi:10.1016/j.gde.2004.12.005. PMID 15661540. (Review).
James P. B. O’Connor, Richard A. D. Carano, Andrew R. Clamp, Jed Ross, Calvin C. K. Ho, Alan Jackson, Geoff J. M. Parker, Chris J. Rose, Franklin V. Peale, Michel Friesenhahn, Claire L. Mitchell, Yvonne Watson, Caleb Roberts, Lynn Hope, Sue Cheung, Hani Bou Reslan, Mary Ann T. Go, Glenn J. Pacheco, Xiumin Wu, Tim C. Cao, Sarajane Ross, Giovanni A. Buonaccorsi, Karen Davies, Jurjees Hasan, Paula Thornton, Olivia del Puerto, Napoleone Ferrara, Nicholas van Bruggen, Gordon C. Jayson: Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. In: Clinical Cancer Research. Band 15, Nr. 21, November 2009, S. 6674–6682, doi:10.1158/1078-0432.CCR-09-0731. PMID 19861458.
Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. Chen, Paul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. In: Nature medicine. Band 10, Nr. 2, Februar 2004, S. 145–147, doi:10.1038/nm988. PMID 14745444, PMC 2693485 (freier Volltext).
Seiji Mabuchi, Yoshito Terai, Kenichiro Morishige, Akiko Tanabe-Kimura, Hiroshi Sasaki, Masanori Kanemura, Satoshi Tsunetoh, Yoshimichi Tanaka, Masahiro Sakata, Robert A. Burger, Tadashi Kimura, Masahide Ohmichi: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. In: Clinical cancer research. Band 14, Nr. 23, Dezember 2008, S. 7781–7789, doi:10.1158/1078-0432.CCR-08-0243. PMID 19047105.
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski, Peter Valent: Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. In: Molecular Oncology. Band 4, Nr. 2, April 2010, S. 150–160, doi:10.1016/j.molonc.2010.01.002. PMID 20106729.
Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, Al B. Benson III: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. In: Clinical cancer research. Band 13, Nr. 13, Juli 2007, S. 3942–3950, doi:10.1158/1078-0432.CCR-07-0278. PMID 17606728.
Rakesh K. Jain: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. In: Science. Band 307, Nr. 5706, Januar 2005, S. 58–62, doi:10.1126/science.1104819. PMID 15637262. (Review).
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, Fairooz Kabbinavar: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. In: The New England journal of medicine. Band 350, Nr. 23, Juni 2004, S. 2335–2342, doi:10.1056/NEJMoa032691. PMID 15175435.
Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, Al B. Benson III: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 25, Nr. 12, April 2007, S. 1539–1544, doi:10.1200/JCO.2006.09.6305. PMID 17442997.
Alan Sandler, Robert Gray, Michael C. Perry, Julie Brahmer, Joan H. Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H. Johnson: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band 355, Nr. 24, Dezember 2006, S. 2542–2550, doi:10.1056/NEJMoa061884. PMID 17167137.
G. Goeckenjan, H. Sitter, M. Thomas, D. Branscheid, M. Flentje, F. Griesinger, N. Niederle, M. Stuschke, T. Blum, K.-M. Deppermann, J. H. Ficker, L. Freitag, A. S. Lübbe, T. Reinhold, E. Späth-Schwalbe, D. Ukena, M. Wickert, M. Wolf, S. Andreas, T. Auberger, R. P. Baum, B. Baysal, J. Beuth, H. Bickeböller, A. Böcking, R. M. Bohle, I. Brüske, O. Burghuber, N. Dickgreber, S. Diederich, H. Dienemann, W. Eberhardt, S. Eggeling, T. Fink, B. Fischer, M. Franke, G. Friedel, T. Gauler, S. Gütz, H. Hautmann, A. Hellmann, D. Hellwig, F. Herth, C. P. Heußel, W. Hilbe, F. Hoffmeyer, M. Horneber, R. M. Huber, J. Hübner, H.-U. Kauczor, K. Kirchbacher, D. Kirsten, T. Kraus, S. M. Lang, U. Martens, A. Mohn-Staudner, K.-M. Müller, J. Müller-Nordhorn, D. Nowak, U. Ochmann, B. Passlick, I. Petersen, R. Pirker, B. Pokrajac, M. Reck, S. Riha, C. Rübe, A. Schmittel, N. Schönfeld, W. Schütte, M. Serke, G. Stamatis, M. Steingräber, M. Steins, Erich Stoelben, L. Swoboda, H. Teschler, H. W. Tessen, M. Weber, A. Werner, H.-E. Wichmann, E. Irlinger Wimmer, C. Witt, H. Worth: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. In: Pneumologie. Band 64, 2010, S. e1–e164, doi:10.1055/s-0029-1243837.
T. Seto, T. Kato, M. Nishio, K. Goto, S. Atagi, Y. Hosomi, N. Yamamoto, T. Hida, M. Maemondo, K. Nakagawa, S. Nagase, I. Okamoto, T. Yamanaka, K. Tajima, R. Harada, M. Fukuoka, N. Yamamoto: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. In: Lancet Oncol. 15(11), 2014, S. 1236–1244. doi:10.1016/S1470-2045(14)70381-X
Robert Gray, Suman Bhattacharya, Christopher Bowden, Kathy Miller, Robert L. Comis: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 27, Nr. 30, Oktober 2009, S. 4966–4972, doi:10.1200/JCO.2008.21.6630. PMID 19720913, PMC 2799052 (freier Volltext).
Nicholas J. Robert, Véronique Diéras, John Glaspy, Adam M. Brufsky, Igor Bondarenko, Oleg N. Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Y.T. Chan, Xian Zhou, See-Chun Phan, Joyce O'Shaughnessy: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 29, Nr. 10, April 2011, S. 1252–1260, doi:10.1200/JCO.2010.28.0982. PMID 21383283.
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. In: The Lancet. Band 370, 2007, S. 2103–2111, doi:10.1016/S0140-6736(07)61904-7. PMID 18156031.
Börje Ljungberg, Nigel C. Cowan, Damian C. Hanbury, Milan Hora, Markus A. Kuczyk, Axel S. Merseburger, Jean-Jacques Patard, Peter F.A. Mulders, Ioanel C. Sinescu: EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398–406, doi:10.1016/j.eururo.2010.06.032. PMID 20633979.
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang: Incorporation of bevacizumab in the primary treatment of ovarian cancer. In: The New England Journal of Medicine. Band 365, Nr. 26, Dezember 2011, S. 2473–2483, doi:10.1056/NEJMoa1104390. PMID 22204724.
Mustafa Khasraw u. a.: Antiangiogenic therapy for high-grade glioma. In: The Cochrane Database of Systematic Reviews. Nr.9, 22. September 2014, S.CD008218, doi:10.1002/14651858.CD008218.pub3, PMID 25242542.
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011 Apr 1;79(5):1487-95. doi:10.1016/j.ijrobp.2009.12.061
Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt: Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. In: The Cochrane Database of Systematic Reviews. Band 11, Nr. 7, 2012, doi:10.1002/14651858.CD008941.pub2
L. Wu, D. Acón, A. Wu, M. Wu: Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm? In: Taiwan journal of ophthalmology. Band 9, Nummer 4, 2019 Oct-Dec, S. 216–223, doi:10.4103/tjo.tjo_67_19, PMID 31942426, PMC 6947741 (freier Volltext) (Review).
L. Moja u. a.: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. In: Cochrane Database Syst Rev. 9, 2014, CD011230. PMID 25220133; doi:10.1002/14651858.CD011230.pub2
Franz Grehn, Thomas Klink: Nachsorge nach Glaukomoperationen. In: Zeitschrift für praktische Augenheilkunde & augenärztliche Fortbildung. Band 30, 2009, S. 235–243, kaden-verlag.de (PDF; 771 kB)
Judah Folkman: Tumor Angiogenesis. In: Robert C. Bast, Jr., Donald W. Kufe, Raphael E Pollock, Ralph R. Weichselbaum, James F Holland, Emil Frei, III: Cancer Medicine. 5th edition. Dekker, Hamilton u. a. 2000, ISBN 1-55009-113-1, S. 132–152, (online)
Masahiro Inoue, Jeffrey H. Hager, Napoleone Ferrara, Hans-Peter Gerber, Douglas Hanahan: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. In: Cancer Cell. Band 1, Nr. 2, März 2002, S. 193–202, doi:10.1016/S1535-6108(02)00031-4. PMID 12086877.
Peter Baluk, Hiroya Hashizume, Donald M. McDonald: Cellular abnormalities of blood vessels as targets in cancer. In: Current opinion in genetics & development. Band 15, Nr. 1, Februar 2005, S. 102–111, doi:10.1016/j.gde.2004.12.005. PMID 15661540. (Review).
James P. B. O’Connor, Richard A. D. Carano, Andrew R. Clamp, Jed Ross, Calvin C. K. Ho, Alan Jackson, Geoff J. M. Parker, Chris J. Rose, Franklin V. Peale, Michel Friesenhahn, Claire L. Mitchell, Yvonne Watson, Caleb Roberts, Lynn Hope, Sue Cheung, Hani Bou Reslan, Mary Ann T. Go, Glenn J. Pacheco, Xiumin Wu, Tim C. Cao, Sarajane Ross, Giovanni A. Buonaccorsi, Karen Davies, Jurjees Hasan, Paula Thornton, Olivia del Puerto, Napoleone Ferrara, Nicholas van Bruggen, Gordon C. Jayson: Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. In: Clinical Cancer Research. Band 15, Nr. 21, November 2009, S. 6674–6682, doi:10.1158/1078-0432.CCR-09-0731. PMID 19861458.
Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. Chen, Paul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. In: Nature medicine. Band 10, Nr. 2, Februar 2004, S. 145–147, doi:10.1038/nm988. PMID 14745444, PMC 2693485 (freier Volltext).
Seiji Mabuchi, Yoshito Terai, Kenichiro Morishige, Akiko Tanabe-Kimura, Hiroshi Sasaki, Masanori Kanemura, Satoshi Tsunetoh, Yoshimichi Tanaka, Masahiro Sakata, Robert A. Burger, Tadashi Kimura, Masahide Ohmichi: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. In: Clinical cancer research. Band 14, Nr. 23, Dezember 2008, S. 7781–7789, doi:10.1158/1078-0432.CCR-08-0243. PMID 19047105.
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski, Peter Valent: Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. In: Molecular Oncology. Band 4, Nr. 2, April 2010, S. 150–160, doi:10.1016/j.molonc.2010.01.002. PMID 20106729.
Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, Al B. Benson III: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. In: Clinical cancer research. Band 13, Nr. 13, Juli 2007, S. 3942–3950, doi:10.1158/1078-0432.CCR-07-0278. PMID 17606728.
Rakesh K. Jain: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. In: Science. Band 307, Nr. 5706, Januar 2005, S. 58–62, doi:10.1126/science.1104819. PMID 15637262. (Review).
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, Fairooz Kabbinavar: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. In: The New England journal of medicine. Band 350, Nr. 23, Juni 2004, S. 2335–2342, doi:10.1056/NEJMoa032691. PMID 15175435.
Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, Al B. Benson III: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 25, Nr. 12, April 2007, S. 1539–1544, doi:10.1200/JCO.2006.09.6305. PMID 17442997.
Alan Sandler, Robert Gray, Michael C. Perry, Julie Brahmer, Joan H. Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H. Johnson: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band 355, Nr. 24, Dezember 2006, S. 2542–2550, doi:10.1056/NEJMoa061884. PMID 17167137.
Robert Gray, Suman Bhattacharya, Christopher Bowden, Kathy Miller, Robert L. Comis: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 27, Nr. 30, Oktober 2009, S. 4966–4972, doi:10.1200/JCO.2008.21.6630. PMID 19720913, PMC 2799052 (freier Volltext).
Nicholas J. Robert, Véronique Diéras, John Glaspy, Adam M. Brufsky, Igor Bondarenko, Oleg N. Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Y.T. Chan, Xian Zhou, See-Chun Phan, Joyce O'Shaughnessy: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. In: Journal of clinical oncology. Official journal of the American Society of Clinical Oncology. Band 29, Nr. 10, April 2011, S. 1252–1260, doi:10.1200/JCO.2010.28.0982. PMID 21383283.
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. In: The Lancet. Band 370, 2007, S. 2103–2111, doi:10.1016/S0140-6736(07)61904-7. PMID 18156031.
Börje Ljungberg, Nigel C. Cowan, Damian C. Hanbury, Milan Hora, Markus A. Kuczyk, Axel S. Merseburger, Jean-Jacques Patard, Peter F.A. Mulders, Ioanel C. Sinescu: EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398–406, doi:10.1016/j.eururo.2010.06.032. PMID 20633979.
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang: Incorporation of bevacizumab in the primary treatment of ovarian cancer. In: The New England Journal of Medicine. Band 365, Nr. 26, Dezember 2011, S. 2473–2483, doi:10.1056/NEJMoa1104390. PMID 22204724.
Mustafa Khasraw u. a.: Antiangiogenic therapy for high-grade glioma. In: The Cochrane Database of Systematic Reviews. Nr.9, 22. September 2014, S.CD008218, doi:10.1002/14651858.CD008218.pub3, PMID 25242542.
L. Wu, D. Acón, A. Wu, M. Wu: Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm? In: Taiwan journal of ophthalmology. Band 9, Nummer 4, 2019 Oct-Dec, S. 216–223, doi:10.4103/tjo.tjo_67_19, PMID 31942426, PMC 6947741 (freier Volltext) (Review).
L. Moja u. a.: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. In: Cochrane Database Syst Rev. 9, 2014, CD011230. PMID 25220133; doi:10.1002/14651858.CD011230.pub2
